Ticagrelor NDC 0480-2695

NDC codes

FDA NDC Directory

Product NDC (as listed)0480-2695Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00480-2695Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0480-2695-06	00480269506	60 TABLET, FILM COATED in 1 BOTTLE (0480-2695-06)Marketed from May 1, 2025

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Ticagrelor
Generic name (nonproprietary): ticagrelor
Active ingredients: Ticagrelor — 90 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Teva Pharmaceuticals, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 208390
Marketing start: May 1, 2025
Listing expires: Dec 31, 2027
Other FDA classes: Cytochrome P450 3A4 Inhibitors (Mechanism)Decreased Platelet Aggregation (Physiologic effect)P-Glycoprotein Inhibitors (Mechanism)P2Y12 Receptor Antagonists (Mechanism)
Identifiers: Product ID 0480-2695_c5291270-45cd-4b98-9260-c046fa74099bSPL ID c5291270-45cd-4b98-9260-c046fa74099bSPL set ID 1bbdc202-bbe4-4aec-b4e9-1f1feb41d819RxCUI 1116635, 1666332UNII GLH0314RVCUPC 0304802695069, 0304802688061
Pharmacologic class: P2Y12 Platelet Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400480269506 followed by a unit qualifier and the quantity

Package 00480-2695-06. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 27, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Ticagrelor is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor tablets also reduce the risk of stent thrombosis in patients who have been stented for treatment of ACS. ( 1.1 ) to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of ticagrelor was established in a population with type 2 diabetes mellitus (T2DM). ( 1.2 ) to reduce the risk of s…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 208390

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 208390
Product	Strength	Form · route	Labeler	Product NDC
Ticagrelor	Ticagrelor 60 mg/1	Tablet, Film coatedOral	Teva Pharmaceuticals, Inc.	0480-2688